PulseSight reports preliminary PST-611 signals in a six-person Phase I study

At EURETINA 2026, PulseSight reported new results from its first-in-human Phase I study of PST-611, an investigational treatment for geographic atrophy (GA), an advanced form of dry age-related macular degeneration.

The small study treated six people with a single dose at two dose levels and followed them for about four months. The trial’s main purpose was to assess safety and tolerability—not to establish efficacy.

The company reported early anatomical and functional signals in five of the six participants. Across the group, it said measured biomarker growth rates fell by 35–52% compared with pre-treatment rates; reported examples included a 40% reduction in the RPE depletion growth rate and reductions in ellipsoid-zone depletion and thickness-loss rates.

Participants reportedly described spontaneous improvements in everyday vision activities. These observations are preliminary and do not demonstrate that the treatment improves or preserves vision.

PulseSight said the study met its safety and tolerability objectives. The company plans to advance PST-611 toward a Phase IIa study, but larger, controlled trials are needed to determine whether the apparent signals are real and clinically meaningful.